Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rani Therapeutics Holdings Inc Cl A (RANI)

Rani Therapeutics Holdings Inc Cl A (RANI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 96,480
  • Shares Outstanding, K 123,692
  • Annual Sales, $ 1,630 K
  • Annual Income, $ -29,670 K
  • EBIT $ -38 M
  • EBITDA $ -37 M
  • 60-Month Beta 0.64
  • Price/Sales 62.95
  • Price/Cash Flow N/A
  • Price/Book 2.43
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.59
  • Most Recent Earnings $-0.07 on 03/26/26
  • Next Earnings Date 05/12/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 490.72% (+40.20%)
  • Historical Volatility 103.34%
  • IV Percentile 63%
  • IV Rank 39.73%
  • IV High 1,124.40% on 05/22/25
  • IV Low 73.08% on 09/09/25
  • Expected Move (DTE 6) 0.1105 (14.93%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 33
  • Volume Avg (30-Day) 330
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 68,705
  • Open Int (30-Day) 69,552
  • Expected Range 0.6295 to 0.8505

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.06
  • Number of Estimates 1
  • High Estimate $-0.06
  • Low Estimate $-0.06
  • Prior Year $-0.22
  • Growth Rate Est. (year over year) +72.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6800 +8.82%
on 04/01/26
1.3800 -46.38%
on 03/11/26
-0.5900 (-44.36%)
since 03/10/26
3-Month
0.6800 +8.82%
on 04/01/26
1.5400 -51.95%
on 01/12/26
-0.6600 (-47.14%)
since 01/09/26
52-Week
0.3870 +91.21%
on 07/15/25
3.8700 -80.88%
on 10/22/25
-0.3900 (-34.51%)
since 04/10/25

Most Recent Stories

More News
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

RANI : 0.7400 (-5.13%)
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital...

RANI : 0.7400 (-5.13%)
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

RANI : 0.7400 (-5.13%)
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

RANI : 0.7400 (-5.13%)
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

RANI : 0.7400 (-5.13%)
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

- A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill ® capsule versus subcutaneous...

RANI : 0.7400 (-5.13%)
Rani Therapeutics to Participate in the Evercore Healthcare Conference

SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

RANI : 0.7400 (-5.13%)
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara...

RANI : 0.7400 (-5.13%)
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

RANI : 0.7400 (-5.13%)
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

RANI : 0.7400 (-5.13%)

Business Summary

Rani Therapeutics Holdings Inc. is a clinical stage biotherapeutics company. It focused on advancing technologies to enable the development of orally administered biologics. Rani Therapeutics Holdings Inc. is based in SAN JOSE, Calif.

See More

Key Turning Points

3rd Resistance Point 0.8646
2nd Resistance Point 0.8318
1st Resistance Point 0.7859
Last Price 0.7400
1st Support Level 0.7072
2nd Support Level 0.6744
3rd Support Level 0.6285

See More

52-Week High 3.8700
Fibonacci 61.8% 2.5395
Fibonacci 50% 2.1285
Fibonacci 38.2% 1.7175
Last Price 0.7400
52-Week Low 0.3870

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.